Waldencast plc(US:WALD)2025-03-19 19:01Financial Performance - FY 2024 - Waldencast's Net Revenue reached $273.9 million, with a Comparable Net Revenue Growth of 27.5%[39] - The Adjusted Gross Profit was $203.6 million, representing a 74.3% Adjusted Gross Margin[39] - Adjusted EBITDA stood at $40.3 million, resulting in a 14.7% Adjusted EBITDA Margin[39] - Adjusted Free Cash Flow was $31.7 million, with an Adjusted EBITDA to Adjusted Free Cash Flow Conversion of 78.8%[41] Financial Performance - Q4 2024 - Net Revenue for Q4 2024 was $72.1 million, showing a 29.4% Comparable Net Revenue Growth[36] - Adjusted Gross Profit for Q4 reached $52.6 million, with a 73.0% Adjusted Gross Margin[36] - Adjusted EBITDA for Q4 was $11.2 million, resulting in a 15.5% Adjusted EBITDA Margin[36] Brand Performance - FY 2024 - Obagi Medical's Net Revenue was $149.3 million, with a Comparable Net Revenue Growth of 30.7% and an Adjusted EBITDA of $30.5 million[80] - Milk Makeup's Net Revenue was $124.6 million, with an Adjusted EBITDA of $29.1 million[80] Future Outlook - For FY 2025, the company anticipates mid-teens Net Revenue growth and mid-to-high teens Adjusted EBITDA Margin[45]